These results suggested that PPD plus Zeb combination therapy not only downregulated PD-L1 expression on tumour cells to relieve the immunosuppression of T cells, but also induced the enhancement of MHC I molecules on tumour cells via CTA, thereby ultimately mounting the visibility of tumour cells to the adaptive immune system in a humanized mouse model. The gene discussed is CD274; the disease is neoplasm.